View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 31, 2020updated 13 Feb 2020 10:15am

Primerdesign launches molecular test for new coronavirus

Clinical diagnostics company Novacyt’s molecular diagnostics division Primerdesign has launched a new molecular research use only (RUO) test for novel coronavirus (2019-nCoV).


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Follow the latest updates of the outbreak on our timeline.

Clinical diagnostics company Novacyt’s molecular diagnostics division Primerdesign has launched a molecular research use only (RUO) test for novel coronavirus (2019-nCoV).

The company developed the test in response to the recent coronavirus outbreak in China.

Primerdesign’s coronavirus test is capable of detecting only the 2019 strain of the virus.

The company believes that this ability of the test differentiates it from other existing tests, which may also react to other related species giving rise to a false diagnosis.

Additionally, the Primerdesign test is stable at ambient temperatures, eliminating the need for cold chain shipping in tropical climates.

Novacyt CEO Graham Mullis said: “Over the last few days, we have seen significant early demand for our genesig 2019-nCoV test from over ten countries. We believe our assay is the first European test to be made available and will be introduced this weekend at the Medlab Expo in the Middle East.

“Our rapid response to this latest virus outbreak is a testament to our core competency of in-vitro diagnostic design, development, manufacturing and commercialisation.”

Designed to run on multiple molecular testing platforms, including Primerdesign’s own genesig q16 and q32 instrument, the test is for use in large, as well as small laboratories.

It can also generate a result in less time, facilitating the quick screening of samples, which could help stop the spread of the virus unnecessarily.

Chinese authorities identified a new strain of the coronavirus named 2019-nCoV earlier this month. The outbreak, which started in the Chinese city of Wuhan, has also spread to other countries.

Following the virus outbreak, China and other countries have imposed significant containment controls and people movement restrictions.

The World Health Organization (WHO) has declared the 2019-nCoV outbreak a global emergency as it continues to spread outside of China.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network